Cure My Disease

Don't miss your cure!

 Log in / Sign up

Tighter oxygen control tested for COPD patients on breathing machines

NCT ID NCT07842510

Disease control Sponsor: Hôpital Universitaire Taher Sfar Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 25, 2026 · Last updated Sep 25, 2026

Summary

Researchers are testing whether keeping blood oxygen levels between 88% and 92% helps ICU patients with acute exacerbations of COPD. The trial compares this controlled oxygen strategy with standard care, which aims for oxygen levels above 94%. The main goal is to see if controlled oxygen reduces the total time patients need mechanical ventilation, with secondary checks on 28-day mortality, ICU stay length, and complications from too much oxygen. The study enrolls 240 adults aged 40 and older admitted to the ICU for a COPD flare-up.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
controlled oxygen therapy, where oxygen delivery is adjusted to keep blood oxygen saturation between 88% and 92%
What this could lead to
If controlled oxygen therapy helps, it could shorten the time patients spend on breathing machines and reduce deaths in the ICU. It could also give critical care teams a clearer target for oxygen levels in COPD flare-ups.
What could go wrong
This is a single trial in one hospital system, so results may not apply everywhere. Oxygen targets are hard to keep steady in very sick patients, and the study may not show a clear difference between the two approaches.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 240 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jan 2026

Expected to finish

Dec 2028

An estimate. End dates often move.

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

40 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥ 40 years * Established diagnosis of chronic obstructive pulmonary disease (COPD) according to the Global Initiative for Chronic Obstructive Lung Disease (GOLD) criteria * Admission to the intensive care unit for an acute exacerbation of COPD, with or without respiratory acidosis * Written informed consent provided by the participant or their legally authorized representative Exclusion Criteria: * Endotracheal intubation performed before enrollment * Severe decompensated heart failure with a left ventricular ejection fraction \< 30% * Active terminal malignancy * Refusal to participate in the study

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acute exacerbation of COPD are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic obstructive pulmonary disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Acute exacerbation of COPD Chronic obstructive pulmonary disease (COPD) Controlled oxygen therapy Intensive care unit (ICU) Mechanical ventilation complication

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    2 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Dhouha Ben Braiek

    NOT_YET_RECRUITING

    Kairouan, Tunisia

  • Taher Sfar Mahdia Hospital

    RECRUITING

    Mahdia, Mahdia Governorate, 5100, Tunisia

More trials for these conditions

Other studies related to the condition(s) this trial covers.